CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy

Experimental and Therapeutic Medicine

Volumn 3, Issue 5, 2012, Pages 811-817

  Jeong, Byung Joo ^a   Liang, Zhe Long ^a   Huang, Song Mei ^a   Lim, Jae Sung ^a   Kim, Jin Man ^a   Lee, Hyo Jin ^a  

^a Chungnam National University   (South Korea)

Author keywords

CD44; Prognosis; Renal cell carcinoma; Survival

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CORRELATION ANALYSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84863357062     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.505     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC and Kwon ED: Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 113: 450-460, 2008.
3. Zisman A, Pantuck AJ, Wieder J, et al: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566, 2002.
4. Klatte T, Seligson DB, Leppert JT, et al: The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 179: 61-66, 2008.
5. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL and Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168: 2395-2400, 2002
7. Patard JJ, Kim HL, Lam JS, et al: Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22: 3316-3322, 2004.
8. Zisman A, Pantuck AJ, Dorey F, et al: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19: 1649-1657, 2001.
9. Lam JS, Klatte T, Kim HL, et al: Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol 65: 235-262, 2008.
10. Volpe A and Patard JJ: Prognostic factors in renal cell carcinoma. World J Urol 28: 319-327, 2010.
11. Marhaba R and Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231, 2004.
12. Naor D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997.
13. Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF and Holzbeierlein J: Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 131: 261-267, 2007.
14. Liao HX, Lee DM, Levesque MC and Haynes BF: N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. J Immunol 155: 3938-3945, 1995.
15. Lim SD, Young AN, Paner GP and Amin MB: Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch 452: 49-55, 2008.
16. Bamias A, Chorti M, Deliveliotis C, et al: Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology 62: 368-373, 2003.
17. Wu ST, Sun GH, Hsieh DS, Chen A, Chen HI, Chang SY and Yu D: Correlation of CD44v5 expression with invasiveness and prognosis in renal cell carcinoma. J Formos Med Assoc 102: 229-233, 2003.
18. Paradis V, Ferlicot S, Ghannam E, et al: CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urol 16: 1984-1987, 1999.
19. Rioux-Leclercq N, Epstein JI, Bansard JY, et al: Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 32: 1209-1215, 2001.
20. Lucin K, Matusan K, Dordević G and Stipić D: Prognostic significance of CD44 molecule in renal cell carcinoma. Croat Med J 45: 703-708, 2004.
21. Gilcrease MZ, Guzman-Paz M, Niehans G, Cherwitz D, McCarthy JB and Albores-Saavedra J: Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86: 2320-2326, 1999.
22. Heider KH, Ratschek M, Zatloukal K and Adolf GR: Expression of CD44 isoforms in human renal cell carcinomas. Virchows Arch 428: 267-273, 1996.
23. Matusan K, Dordevic G, Mozetic V and Lucin K: Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res 11: 108-113, 2005.
24. Lee SM, Lee KE, Chang HJ, et al: Prognostic significance of CD44s expression in biliary tract cancers. Ann Surg Oncol 15: 1155-1160, 2008.
25. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020, 2009.
26. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M and Pals ST: Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68: 3655-3661, 2008.
27. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F and Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174, 2006.
28. Krause DS, Lazarides K, von Andrian UH and van Etten RA: Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12: 1175-1180, 2006.
29. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH and Joo JK: Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 59: 241-246, 2009.
30. Terpe HJ, Störkel S, Zimmer U, Anquez V, Fischer C, Pantel K and Günthert U: Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 148: 453-463, 1996.
31. Zolota V, Tsamandas AC, Melachrinou M, Batistatou A and Scopa C: Expression of CD44 protein in renal cell carcinomas: association with p53 expression. Urol Oncol 7: 13-17, 2002.